. Author manuscript; available in PMC: 2013 Dec 17.

Published in final edited form as: Bioorg Med Chem. 2011 Mar 1;19(6):10.1016/j.bmc.2011.01.047. doi: 10.1016/j.bmc.2011.01.047

Table 3.

Anti-HIV activity of selected novel potent derivatives

Comp. in	Anti-HIV-1 activity in PBMCs^a		Slope	R	Cytotoxicity (IC₅₀, μM)
Comp. in	EC₅₀ (μM)^b	EC₉₀ (μM)^b	Slope	R	PBMCs	CEM
15	8.7	21.0	2.5±0.61	0.97	24.4	27.5
17	13.9	26.0	3.5	1.0	22.1	23.8
25	7.3	20.3	2.2±0.96	0.91	22.7	19.0
49	10.1	24.3	2.5±0.89	0.94	39.1	20.7
8	30.8	52.7	4.1	1.0	44.0	40.2
AZT	0.0025	0.01	1.6±0.30	0.96	>100	56.1
L-706,908	5.7±4.7^c	N/A	N/A	N/A	N/A	N/A

Human peripheral blood mononuclear cells(PBMCs),

EC50 and EC90 are the effective concentrations inhibiting 50% and 90% HIV replication, respectively.

In the human leukemic T–cell line MOLT -4; in that assay the EC50 of AZT was 0.001 μM.